The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis and uterine fibroids , as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. The Manager will also serve as a key technical resource for stock-based compensation accounting and related disclosures, support SOX 404 activities over financial reporting processes, and partner closely with Accounting, Finance, Legal, HR, Payroll, Internal Audit, external auditors, and other stakeholders.